Taken together, these SMARCA4-deficient cell lines previously characterized as SCLC-Y may serve as patient derived preclinical models of SMARCA4-UT to accelerate the discovery of new therapeutics for this aggressive malignancy. Here, SMARCA4 is linked to small cell lung carcinoma.